Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK2 | O75116 | 12/20 | 1.00 |
| ▸ | ROCK1 | Q13464 | 11/20 | 1.00 |
| ▸ | PRKD3 | O94806 | 5/20 | 0.62 |
| ▸ | PRKCG | P05129 | 5/20 | 0.62 |
| ▸ | PRKCB | P05771 | 5/20 | 0.62 |
| ▸ | PRKCA | P17252 | 5/20 | 0.62 |
| ▸ | PRKCH | P24723 | 5/20 | 0.62 |
| ▸ | PRKCI | P41743 | 5/20 | 0.62 |
| ▸ | PRKCE | Q02156 | 5/20 | 0.62 |
| ▸ | PRKCQ | Q04759 | 5/20 | 0.62 |
| ▸ | PRKCZ | Q05513 | 5/20 | 0.62 |
| ▸ | PRKCD | Q05655 | 5/20 | 0.62 |
| ▸ | PRKD1 | Q15139 | 5/20 | 0.62 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.62 |
| ▸ | PRKACA | P17612 | 4/20 | 0.62 |
| ▸ | PRKACG | P22612 | 4/20 | 0.62 |
| ▸ | PRKACB | P22694 | 4/20 | 0.62 |
| ▸ | ADORA3 | P0DMS8 | 2/20 | 0.62 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.62 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20644189 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL190414 | 1.00 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| Hydrochloric Acid SCHEMBL29377359 | 0.99 | ROCK2 (0.98) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL19543804 | 0.91 | ROCK2 (0.83) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716157 | 0.87 | ROCK2 (1.00) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL19543799 | 0.87 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716079 | 0.87 | ROCK2 (0.77) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13715989 | 0.85 | ROCK2 (0.78) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL13716058 | 0.85 | ROCK2 (0.78) | ROCK2ROCK1PRKD3PRKCGPRKCB | |
| SCHEMBL4729640 | 0.84 | ROCK2 (0.74) | ROCK2ROCK1PRKD3PRKCGPRKCB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230399311-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399311-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399311-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2023-12-14 | — | — | US | disclosed |
| US-20230399311-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2023-12-14 | — | — | US | disclosed |
| WO-2023240251-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | BioAxone BioSciences, Inc. (US) | 2023-12-14 | — | — | WO | disclosed |
| US-11814361-B2 | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof | BioAxone BioSciences, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11814361-B2 | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof | BioAxone BioSciences, Inc. (US) | 2023-11-14 | — | — | US | disclosed |
| US-11701366-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | BioAxone BioSciences, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-11701366-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | BioAxone BioSciences, Inc. (US) | 2023-07-18 | — | — | US | disclosed |
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | BioAxone BioSciences, Inc. (US) | 2022-03-24 | — | — | US | disclosed |
| WO-2019014322-A1 | KINASE INHIBITORS FOR TREATMENT OF DISEASE | BioAxone BioSciences, Inc. (US) | 2019-01-17 | — | — | WO | disclosed |
| US-20190015404-A1 | KINASE INHIBITORS FOR TREATMENT OF DISEASE | AEGIS THERAPEUTICS, LLC | 2019-01-17 | — | — | US | disclosed |
| US-20170313680-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | AEGIS THERAPEUTICS, LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170313680-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | AEGIS THERAPEUTICS, LLC | 2017-11-02 | — | — | US | disclosed |
| US-20170246181-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2017-08-31 | — | — | US | disclosed |
| US-20170246181-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2017-08-31 | — | — | US | disclosed |
| US-9687483-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors | BioAxone BioSciences, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-9687483-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with Rho kinase inhibitors | BioAxone BioSciences, Inc. (US) | 2017-06-27 | — | — | US | disclosed |
| US-20160213664-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2016-07-28 | — | — | US | disclosed |
| US-20160213664-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | AEGIS THERAPEUTICS, LLC | 2016-07-28 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220089567-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | RHOA, ARHGDIA, ROCK1 | ROCK2 4/4885ROCK1 3/4885PRKD3 423/4885 |
| US-20170246181-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | ROCK2 1/4885ROCK1 2/4885PRKD3 297/4885 |
| US-20230399311-A1 | POLYMORPHS OF SUBSTITUTED ISOQUINOLINE-BASED RHO KINASE INHIBITORS | ROCK1, ROCK2, RAC1 | ROCK2 2/4885ROCK1 1/4885PRKD3 152/4885 |
| US-20160213664-A1 | TREATMENT OF CEREBRAL CAVERNOUS MALFORMATIONS AND CEREBRAL ANEURYSMS WITH RHO KINASE INHIBITORS | ROCK2, ROCK1, CIT | ROCK2 1/4885ROCK1 2/4885PRKD3 297/4885 |
| US-11701366-B2 | Treatment of cerebral cavernous malformations and cerebral aneurysms with rho kinase inhibitors | ROCK2, ROCK1, CIT | ROCK2 1/4885ROCK1 2/4885PRKD3 297/4885 |
| US-20190015404-A1 | KINASE INHIBITORS FOR TREATMENT OF DISEASE | PRKG2, PTGIS, PRKG1 | ROCK2 71/4885ROCK1 84/4885PRKD3 145/4885 |
| US-11814361-B2 | Rho kinase inhibitor BA-1049 (R) and active metabolites thereof | RHOA, ARHGDIA, ROCK1 | ROCK2 4/4885ROCK1 3/4885PRKD3 423/4885 |
| US-20170313680-A1 | RHO KINASE INHIBITOR BA-1049 (R) AND ACTIVE METABOLITES THEREOF | ARHGDIA, RHOA, ARHGDIB | ROCK2 9/4885ROCK1 4/4885PRKD3 213/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.